Business Context and Reporting Period
This Form 8-K was filed by Lucid Diagnostics Inc. (LUCD) on November 13, 2023, reporting events that occurred on November 6, 2023. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a leadership appointment within the executive team:
- Appointment: Shaun M. O'Neil was appointed as President of Lucid Diagnostics Inc., effective November 6, 2023.
- Continued Roles: Mr. O'Neil continues to serve as the Chief Operating Officer (COO) of Lucid Diagnostics and as the COO of PAVmed Inc., the Company's parent.
- Related Transactions: The filing states that, other than his service as an officer, Mr. O'Neil has not engaged in any transactions with the Company requiring reporting under Item 404(a) of Regulation S-K.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the executive appointment.
Investor Verification Checklist
- Verify the biographical details and background of Shaun M. O'Neil in the definitive proxy statement on Schedule 14A filed on May 1, 2023.
- Confirm the ongoing relationship and operational structure between Lucid Diagnostics Inc. and its parent company, PAVmed Inc.
- Review subsequent filings for any financial updates, as this 8-K contains no financial metrics.